Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Microbiome in Pediatric Rheumatic Diseases

Matthew Stoll, MD, PhD  |  Issue: April 2016  |  April 15, 2016

It turns out that having a highly diverse intestinal microbiota appears to be of benefit in multiple contexts. For example, decreased alpha diversity has been observed in a variety of disorders, including the intestinal microbiota in obesity, irritable bowel syndrome, psoriatic arthritis and IBD; as well as the skin microbiota in psoriasis, vitiligo and atopic dermatitis.16-22 Although cross-sectional studies do not distinguish cause from consequence, two prospective studies have demonstrated that abnormal diversity may be a poor prognostic factor. One of them was an offshoot of a longitudinal study of children in The Environmental Determinants of Diabetes in the Young (TEDDY) database consisting of young children identified as being at increased risk of diabetes based upon their HLA types. Serial stool samples were obtained from asymptomatic high-risk children, with the results showing that alterations in the microbiota—including decreased alpha diversity—were observed prior to the onset of diabetes, such that there was a clear differentiation between these children compared with controls from the TEDDY study who did not develop diabetes.23 Also, a prospective study evaluating the role of the microbiota in 80 subjects undergoing allogeneic stem cell transplantation revealed three-year survival rates of 36%, 60% and 67% among subjects with baseline diversity levels characterized, respectively, as low, intermediate or high.24 To assess the possibility that low diversity was simply a marker for general ill health, the authors adjusted for a variety of predictors, including the following: age, morbidity, the underlying disease and the nature of the conditioning regimen; here again, low-diversity microbial populations emerged as independent predictors of mortality.

Why is having such a diverse microbiota beneficial? There is no definitive answer to this question. However, it may pertain to the functional potential of the microbiota. As noted above, the human intestinal microbiota contains over 3 million genes, many of which can affect various aspects of human physiology, including nutrition, drug metabolism and bile acid recirculation. Decreased diversity at the taxonomic and genetic level may result in decreased diversity at the metabolic level as well.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As an illustration, we performed whole genome sequencing of fecal microbiota plus fecal water metabolomics analyses on a set of children with ERA/JIA and healthy controls. In the ERA/JIA patients, we identified decreased alpha diversity, decreased abundance of genes coding for known metabolic pathways and decreased fecal metabolites.25 The precise association between these findings and disease awaits further exploration, however.

Altering the Microbiota

TABLE 2: Summary of randomized trials evaluating probiotics in inflammatory arthritis.1 This trial was conducted exclusively through the Internet, so no objective outcomes were obtained.

(click for larger image) Table 2: Summary of randomized trials evaluating probiotics in inflammatory arthritis.1 This trial was conducted exclusively through the Internet, so no objective outcomes were obtained.

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsPediatric ConditionsResearch Rheum Tagged with:gastrointestinal diseasejuvenile rheumatoid arthritisMicrobiomemicrobiotiaPediatricResearchRheumatic Disease

Related Articles

    Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

    April 15, 2016

    The microbiome comprises diverse microbial flora, including bacteria, viruses and fungi, that live on mucosal surfaces, predominantly the skin and digestive tract. Microbes evolved billions of years prior to the development of modern Homo sapiens 200,000 years ago; we have always existed with their ubiquitous presence. Despite this, the first microbe was not visualized until…

    Links Between Gut Bacteria and Rheumatoid Arthritis

    March 19, 2019

    CHICAGO—At the 2018 ACR/ARHP Annual Meeting, Allen C. Steere, MD, delivered the Rheumatology Research Foundation Memorial Lecture honoring the late Charles M. Plotz, MD: Linking Gut Microbial Immunity with Autoimmunity in Joints in Patients with Rheumatoid Arthritis. Dr. Steere is professor of medicine at Harvard Medical School, Boston, and director of translational research in rheumatology…

    The Microbiome

    November 1, 2011

    A voyage to (our inner) Lilliput

    2014 ACR/ARHP Annual Meeting: Microbiota Power

    March 1, 2015

    Gut bacteria may hold clues to breakthrough rheumatic disease treatments

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences